Faeth Therapeutics (FTH) Jumps 72% on EPS Revision; CRMT, LILA Gain
Five stocks detected by our EPS revision screener posted strong gains through June 25. Faeth Therapeutics (FTH) rose 72% after its next-year EPS growth estimate was raised to 93.7%, while Americas Car Mart (CRMT) gained 56% on a 101.7% revision. Liberty Latin America shares (LILA, LILAK) surged 44-47% as their EPS growth estimates were lifted by 132 and 1800 percentage points respectively, and Biodesix (BDSX) added 31% on a modest 2.5pp revision to 40.7%.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FTH | Healthcare | 2026-06-16 | N/A | +72.0% |
| CRMT | Consumer Cyclical | 2026-06-16 | N/A | +56.0% |
| LILA | Communication Services | 2026-06-18 | +131.8pp | +46.5% |
| LILAK | Communication Services | 2026-06-18 | +1799.9pp | +44.7% |
| BDSX | Healthcare | 2026-06-18 | +2.5pp | +30.5% |
Why did FTH stock jump in June 2026?
FTH stock jumped 72.0% (from $14.53 to $24.99) after analysts revised its next-year EPS growth estimate upward to 93.7% on June 16.
The healthcare sector has been buoyed by a wave of positive sentiment around early-stage biotech firms, and Faeth's revision signaled a sharp expected earnings turnaround. No specific company news emerged in the window, suggesting the move was driven purely by the estimate upgrade and sector momentum.
FTH EPS revision history → · Screener snapshot from 2026-06-16 →
FAQ: FTH
Why did FTH stock jump in June 2026?
FTH surged 72% after analysts raised its next-year EPS growth estimate to 93.7% on June 16, from $14.53 to $24.99 by June 25.
Is FTH a buy after the rally?
The 72% gain reflects the magnitude of the EPS revision, but with no additional news, investors should weigh the sustainability of the 93.7% growth estimate against sector risks.
What is FTH's EPS growth estimate?
Faeth Therapeutics' next-year EPS growth estimate stands at 93.7% as of the June 16 revision.
Why did CRMT stock jump in June 2026?
CRMT stock jumped 56.0% (from $2.34 to $3.65) after its next-year EPS growth estimate was revised to 101.7% on June 16.
The consumer cyclical sector has benefited from resilient auto demand, and the estimate revision implies a strong earnings rebound for the used-car retailer. No earnings-related news appeared, confirming the screener's detection of a quiet but powerful estimate upgrade.
CRMT EPS revision history → · Screener snapshot from 2026-06-16 →
FAQ: CRMT
Why did CRMT stock jump recently?
CRMT rose 56% after analysts raised its next-year EPS growth estimate to 101.7% on June 16, pushing the stock from $2.34 to $3.65.
What caused CRMT's surge?
The surge was driven solely by an upward EPS revision—no company-specific news was released—amid strong used-car demand trends in the consumer cyclical sector.
What is CRMT's EPS growth estimate?
Americas Car Mart's next-year EPS growth estimate is 101.7% following the revision detected on June 16.
Why did LILA stock jump in June 2026?
LILA stock jumped 46.5% (from $4.80 to $7.03) after its next-year EPS growth estimate was revised from 208.4% to 340.3% on June 18.
The Communication Services sector in Latin America has seen improving macro conditions, and Liberty Latin America’s large revision signaled a dramatic expected earnings acceleration. No news accompanied the move, underscoring that the estimate upgrade itself was the catalyst.
LILA EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: LILA
Why did LILA stock jump in June 2026?
LILA surged 46.5% after analysts raised its next-year EPS growth estimate from 208.4% to 340.3% on June 18, lifting the stock from $4.80 to $7.03.
Is LILA a buy after the rally?
The 132-percentage-point revision is substantial, but with no news, investors should monitor whether Latin American telecom fundamentals justify the 340% growth estimate.
What caused LILA's surge?
The surge was triggered by a major upward EPS revision detected on June 18, with no other catalysts reported in the period.
Why did LILAK stock jump in June 2026?
LILAK stock jumped 44.7% (from $4.79 to $6.93) after its next-year EPS growth estimate was revised from 413.6% to 2213.6% on June 18.
This extraordinary 1800-percentage-point revision reflects an extreme expected earnings turnaround, likely tied to the same sector trends benefiting Liberty Latin America’s other share class. No company-specific news emerged, reinforcing the revision as the primary driver.
LILAK EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: LILAK
Why did LILAK stock jump recently?
LILAK jumped 44.7% after analysts revised its next-year EPS growth estimate from 413.6% to 2213.6% on June 18, from $4.79 to $6.93.
What is LILAK's EPS growth estimate?
LILAK's next-year EPS growth estimate is 2213.6% following the June 18 revision.
What caused LILAK's surge?
The surge was driven by an unprecedented 1800-percentage-point upward EPS revision, with no other news catalysts in the window.
Why did BDSX stock jump in June 2026?
BDSX stock jumped 30.5% (from $16.81 to $21.94) after analysts raised its next-year EPS growth estimate from 38.2% to 40.7% on June 18.
The Healthcare sector has been buoyed by a strong diagnostic testing environment, and the modest 2.5pp revision was enough to propel Biodesix higher as the market focused on accelerating earnings. No news appeared, confirming the revision's pricing impact.
BDSX EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: BDSX
Why did BDSX stock jump in June 2026?
BDSX rose 30.5% after analysts nudged its next-year EPS growth estimate from 38.2% to 40.7% on June 18, taking the stock from $16.81 to $21.94.
Is BDSX a buy after the rally?
The 30.5% gain on a small revision suggests strong market conviction, but investors should confirm whether the 40.7% growth estimate is sustainable.
What caused BDSX's surge?
The surge was triggered by a slight upward EPS revision detected on June 18, with supportive healthcare sector momentum amplifying the move.
Today's top performers all share a common theme: upward EPS revisions detected by our screener translated into double-digit price gains, even without accompanying news. This pattern suggests that earnings estimate momentum remains a powerful driver in a market hungry for growth signals across healthcare, consumer cyclical, and communication services.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →